Bruker Reaches a New 52-Week High at $66.54

As seen on the 24/7 Wall St. homepage on November 9, 2026.

BRKR Bruker

52-week high

Nov 9, 5:00pm ET

$66.54

+2.76% vs prior 52-week high · Sep 30, 2026

Bruker's $66.54 close tops its September 30 peak by 2.76%, a new high for the stock, with the rest of the toolmaker group higher alongside it.

Related stocks today

AMEAMETEKCompetitor+4.2%

Dec 31, 2025 · SEC 10-K
TMOThermo Fisher ScientificCompetitor+3.8%

Dec 31, 2025 · SEC 10-K
AAgilent TechnologiesCompetitor+3.1%

Dec 31, 2025 · SEC 10-K

Moves: Nov 9, 2026 · Alpha Vantage daily close

13 more related stocks · 3 have no US listing

Continue ReadingShow less

Bruker closed at $66.54 on November 9, 2026, clearing its prior 52-week peak set on September 30 by 2.76%. Buyers are now willing to pay more than anyone has paid in the last year.

Competitors AMETEK, Thermo Fisher Scientific, and Agilent Technologies all posted gains on the same session, pointing to sector-wide demand across scientific instrument and analytical toolmakers.

Sources

Mentioned: BRKR, BRKRP, BRUKP, TMO, A, AME

Related Market Updates

AME AMETEK

After-hours

Nov 5, 5:20pm ET

$223.70

-4.48% open $234.18

A 4.48% single-session drop is rare for an industrial technology compounder that normally grinds higher. Keep an eye on whether it stabilizes near the lows or keeps bleeding after hours.

AME AMETEK

Regular session

Nov 5, 1:20pm ET

$223.93

-4.38% open $234.18

A 4.38% slide to $223.93 from a $234.18 open is a rare single-session move for a $51.3 billion industrial compounder that usually grinds rather than gaps. Worth checking whether this is a broad industrial reset or something name-specific.

Biggest movers · At the close Nov 4, 4:10pm ET

Gainers

DUOLDuolingo$162.31+26.8%
OPENOpendoor Technologies$1.99+14.4%
BRKRBruker$63.73+12.8%
LYFTLyft$18.77+12.6%
MRNAModerna$255.26+11.7%

Losers

CIFRCipher Digital$6.46-20.5%
DDOGDatadog$188.37-14.6%
VRTVertiv$204.81-13.2%
CVSCVS Health$80.29-12.2%
PWRQuanta Services$577.78-12.1%

Duolingo closed up 26.8% at $162.31, the biggest move in a 383-stock priority universe that saw double-digit swings on both ends. Datadog, Vertiv, CVS and Quanta all gave up more than 12% in the same session.

AME AMETEK

Regular session

Nov 4, 2:20pm ET

$235.73

-5.82% open $250.31

A 5.82% drop to $235.73 takes roughly $3 billion off a $54 billion market cap, an outsized single session for a name that usually grinds rather than gaps. Keep an eye on whether the $250.31 open gets reclaimed.

BRKR Bruker

Regular session

Nov 4, 11:00am ET

$60.03

-8.74% open $65.78

The selloff landed the same day Bruker filed its Q3 2026 earnings release, erasing roughly $800 million from a life science tools name. Moves this size are rare here, and the selling held into the close.

AME AMETEK

Regular session

Nov 4, 10:20am ET

$236.10

-5.67% open $250.31

A 5.67% slide to $236.11 is an outsized day for a $54 billion industrial compounder that rarely moves like this. Whether buyers step in near this level sets the tone for the rest of the week.

BRKR Bruker

Q3 2026

Nov 4, 7:00am ET

EPS

$0.56

est $0.42 +34.6%

Revenue

$874M

est $865M +1.0%

Cost discipline pushed non-GAAP operating margin up 400 basis points to 16.3%, beating expectations even as a goodwill impairment dragged GAAP results to a loss. Management reaffirmed full-year non-GAAP EPS guidance and pointed to double-digit EPS growth in FY27 behind a fifth straight quarter of book-to-bill above one.

Earnings · 2026 Q3 Frank H Laukien PRESIDENT & CEO, Bruker

Nov 4, 7:00am ET

In the third quarter, we achieved very significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution. Bruker's positive booking trends continued with the fifth consecutive quarter of Bruker Scientific Instruments (BSI) book-to-bill greater than one.

Five straight quarters of orders outpacing shipments at the scientific instruments arm means the $8.6 billion lab-tools maker is building backlog while cost cuts do the heavy lifting on earnings. That combination is what investors in the group have been waiting to see.

Earnings · 2026 Q3 Frank H Laukien PRESIDENT & CEO, Bruker

Nov 4, 7:00am ET

We see strengthening demand in most of our end markets, and in Q3 also in the US academic market. With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.

The US academic market, the biggest overhang on lab tool makers all year, turned in the quarter, and Laukien is now underwriting double-digit EPS growth for FY27 off it. At an $8.6 billion market cap, that guidance is the whole thesis for Bruker.

PODCAST Mad Money w/ Jim Cramer Jim Cramer · 44 min

Nov 3, 7:34pm ET

Mad Money w/ Jim Cramer 11/3/26

Cramer calls the mega caps millstones: Nasdaq rose 0.83% while the Dow fell 197 points
Strong after-hours results from AMD and Arista Networks as proof non-Magnificent-Seven tech can lead
Oracle's $10 billion block priced at $116 and traded to $126, a sign buyers see a floor in tech
Wants a crescendo washout before committing more; Apple's reaction and a Palantir selloff weighed

The leadership baton is being passed to second-tier data center names, and Cramer would rather own companies with clean balance sheets than the big caps issuing debt and equity to stay in the AI race. He is not calling a bottom yet: without a high-volume reversal day, he keeps money elsewhere.

AME AMETEK

Q3 2026

Nov 3, 6:55am ET

EPS

$2.21

est $2.11 +4.8%

Revenue

$2.22B

est $2.13B +4.4%

Full-year adjusted EPS guidance now runs $8.53 to $8.57, up from $8.20 to $8.30, with the newly closed Indicor Instrumentation deal plus organic growth behind a double beat. That raise resets the earnings base for anyone holding here.